secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001157523-22-001411
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q3 net product revenue $232M (+39% YoY); AMVUTTRA Q3 sales $25M; reiterates FY product revenue guide $870-930M
--------------------------------------------------------------------------------

- Q3 2022 GAAP net loss $405.9M ($3.32/sh) vs $204.5M ($1.72/sh) YoY; non-GAAP net loss $193.4M ($1.58/sh) vs $189.8M ($1.59/sh).
- Combined net product revenue $232M: TTR $170M (ONPATTRO $145M, AMVUTTRA $25M), GIVLAARI $46M, OXLUMO $16M.
- Reiterated FY 2022 product revenue guidance $870-$930M; lowered collaboration/royalty guidance to $100-$150M from $175-$225M.
- AMVUTTRA U.S. launch strong: $25M net rev in first full quarter, 475 Start Forms, 46% new patients, 54% switches from ONPATTRO.
- Positive APOLLO-B Phase 3 results for patisiran in ATTR cardiomyopathy; sNDA submission on track for late 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000115752322001411/0001157523-22-001411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000115752322001411/a52953758.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer